|
Stemming
diabetes
The much discussed stem cell research could mark a shift from
insulin injections to injectable beta cell vials creating
a certain permanency in the treatment of diabetes. However,
lot of intricacies need to be dealt with prior to that. Vanessa
Mahapatra finds out the promise these miraculous cells hold.
Clinical
trial — a balancing act
Anoop K Agarwal P D, Principal, Institute of Clinical Research
talks about the need to strike a balance between regulatory
authorities and indigenous research capacities.
Pfizer's
under-trial HIV drug available
Pfizer announced that it plans to establish a multinational
Expanded Access Programme (EAP) to make the investigational
CCR5 antagonist maraviroc, currently in ongoing Phase III
clinical trials available to HIV/AIDS patients with CCR5-tropic
HIV-1, who have limited or no approved treatment options due
to resistance or intolerance.
'Microarray
technology is very powerful'
Agilent Technologies has recently tied up with Genotypic to
provide complete genomics solutions to India's burgeoning
lifesciences market in terms of end-to-end microarray-based
genomics solutions, gene-expression analysis and consulting
services. Dr Raja, CEO, Genotypic India and Chris Tan, Regional
Sales Manager-Genomics, Agilent Technologies, speaks to Express
Pharma about the technology and the tie up. Excerpts:
|
